Reprogramming the future of oncology for all patients

PENROSE
THERAPEUTX

is on a mission to change the future for millions of cancer patients. We are developing novel therapies that target the most aggressive cancer cells through a first-in-class mechanism of action, and demonstrate a high level of selectivity for the reprogrammed cancer mitochondria.  

Discover how we are changing the course of oncology.

PENROSE
THERAPEUTX

is on a mission to change the future for millions of cancer patients. We are developing novel therapies that target the most aggressive cancer cells through a first-in-class mechanism of action, and demonstrate a high level of selectivity for the reprogrammed cancer mitochondria. ​

Discover how we are changing the course of oncology.

OUR SCIENCE

NEW FOCUS

Penrose has developed a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies that kill some of the most difficult to treat cancers. Highly selective oral small molecules target cancer mitochondria in a cooperative fashion, leading to necrotic cell death.

NEW THERAPIES

Our lead program (RP-0320), has demonstrated strong in-vivo efficacy across multiple tumor types as a stand-alone therapy. Two next generation programs are currently entering in-vivo testing.

NEW OUTCOMES

We have re-defined anti-cancer pharmacology with the potential for unprecedented safety and efficacy across many hard to treat cancers.

OUR SCIENCE

NEW FOCUS

Penrose has developed a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies that kill some of the most difficult to treat cancers. Highly selective oral small molecules target cancer mitochondria in a cooperative fashion, leading to necrotic cell death.

NEW THERAPIES

Our lead program (RP-0320), has demonstrated strong in-vivo efficacy across multiple tumor types as a stand-alone therapy. Two next generation programs are currently entering in-vivo testing.

NEW OUTCOMES

We have re-defined anti-cancer pharmacology with the potential for unprecedented safety and efficacy across many hard to treat cancers.

OUR SCIENTIFIC TEAMS

Our core R&D facility, based in Plymouth, MI, is comprised of some of the best scientific minds in academia and research across five major divisions that include chemistry, biology, cellular imaging, pharmacology, and high throughput screening.

LATEST UPDATES

Penrose TherapeuTx Appoints Business Leader Mark de Souza as Chief Executive Officer to Help Drive New Innovations in Oncology​
November 23, 2020

CONTACT US